Oracle Health Sciences has been identified as a leader in the top quartile position of the Everest Group PEAK Matrix Assessment of Life Sciences Clinical Trial Products 2017 — a fact-based analysis of global services providers, solutions and products.
Number one
“We believe our being named a leader and in the top position is further validation of Oracle’s continued momentum in the eClinical space,” said Steve Rosenberg, general manager, Oracle Health Sciences. “We realised some time ago that the way technology was supporting clinical research had to change. The collections of point solutions you see on the market today are not serving the industry’s needs. Our response to this problem is Clinical One. Our vision, resources and technology are designed to carry our customers into the future with a single cloud-based eClinical platform that unifies clinical teams, processes and data in a profound new way.”
The Everest Group report assesses companies, not only on revenue, but also on market impact (market adoption, value delivered and portfolio mix) as well as vision and capability (vision and strategy, functionality, flexibility and ease of deployment, engagement and commercial model and support) to evaluate marketplace success.
“After evaluating Oracle’s vision and capability as well as market impact for their Clinical One Platform, which is approaching clinical technology in a new and innovative manner, we placed them as a Leader. In addition to their market penetration, Oracle’s breadth and depth of capabilities represent what we consider to be a leading solution in the eClinical space,” added Nitish Mittal, practice director, Everest Group.